How much capital is available under the Strategic Financing Agreements?

The press release describes $2 billion in committed capital, comprised of up to $1.25 billion of synthetic royalty funding and up to $750.0 million of corporate debt. The company received the first $250.0 million royalty tranche at closing, and $1.25 billion of the total is at the company's discretion, subject to milestones.

What events trigger additional funding?

Tranche 2 Funding of $250.0 million is triggered by a positive RASolute 302 readout in second-line metastatic PDAC before January 1, 2028, followed by a decision or submission of a New Drug Application. Tranche 3 requires FDA approval for RAS G12-mutated or metastatic PDAC by July 1, 2028. Tranche 4 requires a Net Sales milestone before January 1, 2029, and Tranche 5 Sub and Tranche 5 require a positive first-line PDAC Phase 3 readout before January 1, 2030.

What are the key costs and terms of the term loan?

Term Loans bear interest at three-month term SOFR (3.50% floor) plus 5.75%, paid quarterly. An upfront fee of 2.00% applies on each funding date. Voluntary prepayments carry a make-whole premium before the second anniversary of funding, plus a prepayment premium of 3.00% before the third anniversary and 1.00% thereafter. The loan is secured by substantially all company assets and includes a change-of-control prepayment requirement.

What does the company say about its guidance and cash runway?

As a result of the transactions, the company is removing its cash runway end date guidance. It is also withdrawing its previous 2025 GAAP net loss guidance while it evaluates the accounting treatment of the facility and the decision to pursue independent global development and commercialization. Updated financial guidance is expected in the second-quarter 2025 earnings release.

Can the company be acquired, and how would that affect the agreements?

If the company enters into a definitive change-of-control agreement before the Tranche 2 Trigger, it may cancel the Tranche 2 Funding and its associated royalty payments. Royalty Pharma agrees to cooperate with transferring the Royalty Purchase Agreement to any acquirer. The Term Loan requires prepayment upon a change of control, and if this occurs before the Tranche A Funding Date, the company must pay 1.00% of the Tranche A Loans plus applicable make-whole and prepayment premiums.

RVMD 8-K: Material Agreements, Financial Events & More

01—Abstract

Summary

Summary of the 8-K filed June 24, 2025. Cited figures are marked; the original filing is the authoritative source.

Revolution Medicines, Inc. (Nasdaq: RVMD) entered into a Royalty Purchase Agreement and a Loan Agreement on June 23, 2025 with Royalty Pharma, together described as Strategic Financing Agreements providing up to $2 billion^a in committed capital.

Under the royalty agreement, Royalty Pharma paid an upfront $250.0 million^b in exchange for tiered royalty payments on worldwide net sales of daraxonrasib (RMC-6236) and, if approved for the same indication, zoldonrasib (RMC-9805). Additional royalty tranches totaling up to $1.0 billion of further funding are available at the company's election upon specified triggers, including a positive RASolute 302 readout in second-line pancreatic ductal adenocarcinoma (PDAC) and FDA approval milestones. Total royalty rates for the full scenario are 7.80% on the first $2 billion of annual net sales, 4.55% on $2 billion to $4 billion, and 2.40% on $4 billion to $8 billion.

The Loan Agreement provides a senior secured term loan facility of up to $750.0 million^c from Royalty Pharma Development Funding, LLC, administered by Wilmington Trust, National Association. The first $250.0 million tranche must be drawn within 45 days of FDA marketing approval of daraxonrasib for metastatic PDAC if approval occurs by January 1, 2028. The Term Loans bear interest at three-month term SOFR (3.50% floor) plus 5.75%, interest is payable quarterly, there is no scheduled amortization, and the facility matures on the earlier of six years after the first funding date and December 31, 2032.

The filing also states the company is removing its cash runway end date guidance, withdrawing its prior 2025 GAAP net loss guidance pending evaluation of accounting treatment, and is pursuing independent global development and commercialization of its RAS(ON) inhibitor portfolio. The company's press release states that it retains full strategic and executional control of product development and commercialization. Investors should note the royalty obligations apply for 15 years on certain sales, the loan includes a change-of-control prepayment requirement and secured liens over substantially all company assets, and the agreements contain customary restrictive covenants but no financial covenants.

02—Key points

Key Highlights

Royalty Purchase Agreement: $250.0 million upfront payment from Royalty Pharma in exchange for tiered royalties on daraxonrasib (RMC-6236) and potentially zoldonrasib (RMC-9805) net sales.
Up to $1.25 billion in synthetic royalty funding in five $250.0 million tranches; Tranche 2 ($250.0 million) is due upon a positive RASolute 302 readout in second-line PDAC, before January 1, 2028.
Loan Agreement: up to $750.0 million senior secured term loan in three $250.0 million tranches, with the first tranche tied to FDA approval of daraxonrasib for metastatic PDAC by January 1, 2028.
Loan pricing is three-month term SOFR (3.50% floor) plus 5.75%, interest-only with no scheduled amortization, maturing on the earlier of six years after first funding and December 31, 2032.
Full-scenario total royalty rates of 7.80% (first $2 billion of annual net sales), 4.55% ($2 billion to $4 billion) and 2.40% ($4 billion to $8 billion); royalties on U.S. RMC-6236 sales end 15 years after first U.S. commercial sale.
Company is removing cash runway end date guidance and withdrawing its previous 2025 GAAP net loss guidance, with updated guidance expected in its second-quarter 2025 earnings release.
Company is pursuing an independent global development and commercialization strategy, retaining full strategic and executional control according to the press release.

03—Questions

Frequently Asked Questions

How much capital is available under the Strategic Financing Agreements?
The press release describes $2 billion in committed capital, comprised of up to $1.25 billion of synthetic royalty funding and up to $750.0 million of corporate debt. The company received the first $250.0 million royalty tranche at closing, and $1.25 billion of the total is at the company's discretion, subject to milestones.
What events trigger additional funding?
Tranche 2 Funding of $250.0 million is triggered by a positive RASolute 302 readout in second-line metastatic PDAC before January 1, 2028, followed by a decision or submission of a New Drug Application. Tranche 3 requires FDA approval for RAS G12-mutated or metastatic PDAC by July 1, 2028. Tranche 4 requires a Net Sales milestone before January 1, 2029, and Tranche 5 Sub and Tranche 5 require a positive first-line PDAC Phase 3 readout before January 1, 2030.
What are the key costs and terms of the term loan?
Term Loans bear interest at three-month term SOFR (3.50% floor) plus 5.75%, paid quarterly. An upfront fee of 2.00% applies on each funding date. Voluntary prepayments carry a make-whole premium before the second anniversary of funding, plus a prepayment premium of 3.00% before the third anniversary and 1.00% thereafter. The loan is secured by substantially all company assets and includes a change-of-control prepayment requirement.
What does the company say about its guidance and cash runway?
As a result of the transactions, the company is removing its cash runway end date guidance. It is also withdrawing its previous 2025 GAAP net loss guidance while it evaluates the accounting treatment of the facility and the decision to pursue independent global development and commercialization. Updated financial guidance is expected in the second-quarter 2025 earnings release.
Can the company be acquired, and how would that affect the agreements?
If the company enters into a definitive change-of-control agreement before the Tranche 2 Trigger, it may cancel the Tranche 2 Funding and its associated royalty payments. Royalty Pharma agrees to cooperate with transferring the Royalty Purchase Agreement to any acquirer. The Term Loan requires prepayment upon a change of control, and if this occurs before the Tranche A Funding Date, the company must pay 1.00% of the Tranche A Loans plus applicable make-whole and prepayment premiums.

04—Continue

← View all 8-K filings